ABVC BioPharma, Inc. Common Stock (ABVC) is a publicly traded Healthcare sector company. As of May 21, 2026, ABVC trades at $1.10 with a market cap of $27.43M and a P/E ratio of -2.67. ABVC moved +1.82% today. Year to date, ABVC is -53.19%; over the trailing twelve months it is -19.71%. Its 52-week range spans $0.40 to $5.48. Rallies surfaces ABVC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ABVC BioPharma Boosts Fixed Assets to $12.8 Million via $8 Million Puli Land Acquisition: ABVC’s net property and equipment rose to $12.8 million in 2025 from $511,088 in 2024 due to strategic Asian land acquisitions. The 69,230.9 sqm Puli site is appraised at $8 million and will support medicinal plant cultivation and biotech processing with annual output of $60,000–$360,000.
| Metric | Value |
|---|---|
| Price | $1.10 |
| Market Cap | $27.43M |
| P/E Ratio | -2.67 |
| EPS | $-0.39 |
| Dividend Yield | 0.29% |
| 52-Week High | $5.48 |
| 52-Week Low | $0.40 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-8.38M |
| Gross Margin | 0.00% |
ABVC analyst coverage data. Average price target: $0.00.